文献速递流行病学与生物统计临床试验与 GCP

三联疗法在慢性阻塞性肺疾病管理中的系统综述与荟萃分析

Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2018-11-06

该系统综述与荟萃分析纳入21项随机对照试验,比较三联疗法(LAMA+LABA+ICS)与双联或单药治疗COPD的疗效。结果显示三联疗法显著降低中重度急性加重率,改善谷值FEV1和生活质量,但肺炎风险高于LAMA+LABA双联治疗。

要点

  • 三联疗法较LAMA单药、LAMA+LABA及ICS+LABA均显著降低中重度急性加重率。
  • 三联疗法改善谷值FEV1和健康相关生活质量。
  • 三联疗法肺炎风险显著高于LAMA+LABA双联治疗。

核心结论

  • 在晚期COPD患者中,三联疗法较双联或单药治疗降低中重度急性加重率、改善肺功能和生活质量。

研究设计与样本

  • 系统综述与随机对照试验荟萃分析,纳入21项试验(19篇文献),检索至2018年4月。

主要发现

  • 三联疗法较LAMA单药降低中重度急性加重率(率比0.71,95%CI 0.60至0.85)。
  • 三联疗法较LAMA+LABA降低中重度急性加重率(率比0.78,95%CI 0.70至0.88)。
  • 三联疗法较ICS+LABA降低中重度急性加重率(率比0.77,95%CI 0.66至0.91)。
  • 三联疗法肺炎风险显著高于LAMA+LABA双联治疗(相对风险1.53,95%CI 1.25至1.87)。

关键数值与推荐

  • 三联疗法由LAMA、LABA和ICS组成。
  • 纳入标准为比较三联疗法与双联或单药治疗的COPD随机对照试验。

临床怎么用

  • 对于晚期COPD患者,三联疗法可考虑用于减少中重度急性加重并改善肺功能和生活质量。
  • 使用三联疗法时需关注肺炎风险较LAMA+LABA双联治疗增高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the rate of moderate to severe exacerbations between triple therapy and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease (COPD). DESIGN: Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES: PubMed, Embase, Cochrane databases, and clinical trial registries searched from inception to April 2018. ELIGIBILITY CRITERIA: Randomised controlled trials comparing triple therapy with dual therapy or monotherapy in patients with COPD were eligible. Efficacy and safety outcomes of interest were also available. DATA EXTRACTION AND SYNTHESIS: Data were collected independently. Meta-analyses were conducted to calculate rate ratios, hazard ratios, risk ratios, and mean differences with 95% confidence intervals. Quality of evidence was summarised in accordance with GRADE methodology (grading of recommendations assessment, development, and evaluation). RESULTS: 21 trials (19 publications) were included. Triple therapy consisted of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA), and inhaled corticosteroid (ICS). Triple therapy was associated with a significantly reduced rate of moderate or severe exacerbations compared with LAMA monotherapy (rate ratio 0.71, 95% confidence interval 0.60 to 0.85), LAMA and LABA (0.78, 0.70 to 0.88), and ICS and LABA (0.77, 0.66 to 0.91). Trough forced expiratory volume in 1 second (FEV1) and quality of life were favourable with triple therapy. The overall safety profile of triple therapy is reassuring, but pneumonia was significantly higher with triple therapy than with dual therapy of LAMA and LABA (relative risk 1.53, 95% confidence interval 1.25 to 1.87). CONCLUSIONS: Use of triple therapy resulted in a lower rate of moderate or severe exacerbations of COPD, better lung function, and better health related quality of life than dual therapy or monotherapy in patients with advanced COPD. STUDY REGISTRATION: Prospero CRD42018077033.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Zhu J, Liu Y, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018. PMID: 30401700. doi:10.1136/bmj.k4388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。